AR promotes DNA damage repair in prostate cancer cells after radiation therapy and targeting AR pathway using AR signaling inhibitors (ASI) like Enzalutamide (Enz), Bicalutamide (Bic) are evolving as radiosensitization approaches in the management of prostate cancer (15–17). The gene discussed is AR; the disease is prostate carcinoma.